SeqLL Inc
OTC:ATLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SeqLL Inc
Cash from Financing Activities
SeqLL Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SeqLL Inc
OTC:ATLN
|
Cash from Financing Activities
-$4.6m
|
CAGR 3-Years
-138%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Financing Activities
$3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Danaher Corp
NYSE:DHR
|
Cash from Financing Activities
-$1.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Waters Corp
NYSE:WAT
|
Cash from Financing Activities
-$237.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-11%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Financing Activities
-$757m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-7%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Financing Activities
-$150m
|
CAGR 3-Years
23%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
SeqLL Inc
Glance View
SeqLL, Inc. engages in the design, development, and manufacture of genetic analysis technologies. The company is headquartered in Woburn, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-08-27. The company offers ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing solutions. The company uses its true single molecule sequencing (tSMS) technology. SeqLL offers RNA and specialty DNA sequencing services utilizing tSMS. SeqLL offers a range of RNA sequencing services, including its direct RNA sequencing without conversion to complementary DNA (cDNA). The firm operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies. Its testing services are fully customizable to customers research needs and challenges. Its SeqLL technology is used for various application, such as life sciences research and development, liquid biopsy, clinical diagnostics and microbiome analysis. The tSMS platform offers a sample preparation process.
See Also
What is SeqLL Inc's Cash from Financing Activities?
Cash from Financing Activities
-4.6m
USD
Based on the financial report for Sep 30, 2025, SeqLL Inc's Cash from Financing Activities amounts to -4.6m USD.
What is SeqLL Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-138%
The average annual Cash from Financing Activities growth rates for SeqLL Inc have been -138% over the past three years .
